firmicutes < first < firstly

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references

Number of relevant bibliographic references: 60.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000017 (2020)	Franziska Düver [Allemagne] ; Benedikt Wei Brich [Allemagne] ; Matthias Eyrich [Allemagne] ; Matthias Wölfl [Allemagne] ; Paul G. Schlegel [Allemagne] ; Verena Wiegering [Allemagne]	Viral reactivations following hematopoietic stem cell transplantation in pediatric patients – A single center 11-year analysis
000054 (2020)	Rongda Li [République populaire de Chine] ; Qi Wan [République populaire de Chine] ; Pan Chen [République populaire de Chine] ; Shufen Mao [République populaire de Chine] ; Qiuju Wang [République populaire de Chine] ; Xiaoxin Li [République populaire de Chine] ; Yi Yang [République populaire de Chine] ; Li Dong [République populaire de Chine]	Tocilizumab treatment in Felty's syndrome.
000075 (2020)	Anca D. Askanase [États-Unis] ; Leila Khalili [États-Unis] ; Jill P. Buyon [États-Unis]	Thoughts on COVID-19 and autoimmune diseases
000082 (2020)	Eun-Jung Park [Corée du Sud] ; Hyungjin Kim [Corée du Sud] ; Seung Min Jung [Corée du Sud] ; Yoon-Kyoung Sung [Corée du Sud] ; Han Joo Baek [Corée du Sud] ; Jisoo Lee [Corée du Sud]	The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus
000088 (2020)	N. Ghalandari ; R. J. E. M. Dolhain ; J. M. W. Hazes ; C. L. E. Siezen ; J. W. Van Der Laan ; H. J. M. J. Crijns ; E. P. Van Puijenbroek ; C. J. Van Der Woude	The pre‐ and post‐authorisation data published by the European medicines agency on the use of biologics during pregnancy and lactation
000097 (2020)	Weiyi Tan ; Jamil Aboulhosn	The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease
000144 (2020)	Wolfgang F. Richter [Suisse] ; Hans-Peter Grimm [Suisse] ; Marie-Hélène Gouy [Suisse] ; Susi S Gaard [Danemark] ; Caroline Kreuzer [Suisse] ; Uwe Wessels [Allemagne] ; Dragomir Draganov [Suisse] ; Chris Muenzer [Suisse] ; Tonio Hoche [Suisse]	Subcutaneous Site-of-Absorption Study with the Monoclonal Antibody Tocilizumab in Minipigs: Administration Behind Ear Translates Best to Humans.
000165 (2020)	Chao Zhang [République populaire de Chine] ; Meini Zhang [République populaire de Chine] ; Wei Qiu [République populaire de Chine] ; Hongshan Ma [République populaire de Chine] ; Xinghu Zhang [République populaire de Chine] ; Zilong Zhu [République populaire de Chine] ; Chun-Sheng Yang [République populaire de Chine] ; Dongmei Jia [République populaire de Chine] ; Tian-Xiang Zhang [République populaire de Chine] ; Meng Yuan [République populaire de Chine] ; Yan Feng [République populaire de Chine] ; Li Yang [République populaire de Chine] ; Wenli Lu [République populaire de Chine] ; Chunshui Yu [République populaire de Chine] ; Jeffrey L. Bennett [États-Unis] ; Fu-Dong Shi [République populaire de Chine]	Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.
000167 (2020)	Peter A. Riedell ; Michael R. Bishop	Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas
000178 (2020)	Adelaide Sofia Batalha Figueiredo [Portugal] ; Ana Luísa Oliveira [Portugal] ; Ant Nio Caetano [Portugal] ; Maria Francisca Moraes-Fontes [Portugal]	SAPHO: has the time come for tailored therapy?
000191 (2020)	Yoshiya Tanaka [Japon] ; Hideto Kameda [Japon] ; Kazuyoshi Saito [Japon] ; Yuko Kaneko [Japon] ; Eiichi Tanaka [Japon] ; Shinsuke Yasuda [Japon] ; Naoto Tamura [Japon] ; Keishi Fujio [Japon] ; Takao Fujii [Japon] ; Toshihisa Kojima [Japon] ; Tatsuhiko Anzai [Japon] ; Chikuma Hamada [Japon] ; Yoshihisa Fujino [Japon] ; Shinya Matsuda [Japon] ; Hitoshi Kohsaka [Japon]	Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study.
000197 (2020)	Angela Ceribelli [Italie] ; Francesca Motta [Italie] ; Maria De Santis [Italie] ; Aftab A. Ansari [États-Unis] ; William M. Ridgway [États-Unis] ; M. Eric Gershwin [États-Unis] ; Carlo Selmi [Italie]	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy
000199 (2020)	Tarek Mohamed Abd El-Aziz [États-Unis, Égypte] ; James D. Stockand [États-Unis]	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
000204 (2020)	Jennie H. Best [États-Unis] ; Steven C. Vlad [États-Unis] ; Lenore Tominna [États-Unis] ; Ibrahim Abbass [États-Unis]	Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic.
000208 (2020)	Natalia Maximova [Italie] ; Alessandra Maestro [Italie] ; Davide Zanon [Italie] ; Annalisa Marcuzzi [Italie]	Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration
000218 (2020)	Piero Ruscitti [Italie] ; Paola Cipriani [Italie] ; Vasiliki Liakouli [Italie] ; Daniela Iacono [Italie] ; Ilenia Pantano [Italie] ; Francesco Caso [Italie] ; Federico Perosa [Italie] ; Fabiola Atzeni [Italie] ; Francesco Paolo Cantatore [Italie] ; Raffaele Scarpa [Italie] ; Francesco Ciccia [Italie] ; Roberto Giacomelli [Italie]	Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort.
000221 (2020)	Yao-Chung Liu [Taïwan] ; Ting-An Lin [Taïwan] ; Hao-Yuan Wang [Taïwan] ; Po-Shen Ko [Taïwan] ; Chia-Jen Liu [Taïwan] ; Liang-Tsai Hsiao [Taïwan] ; Sheng-Hsuan Chien [Taïwan] ; Jyh-Pyng Gau [Taïwan]	Pralatrexate as a bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage extranodal nasal-type natural killer/T cell lymphoma refractory to first-line chemotherapy: a case report
000222 (2020)	Paul Emery [Royaume-Uni] ; Sarah Horton [Royaume-Uni] ; Raluca Bianca Dumitru [Royaume-Uni] ; Kamran Naraghi [Royaume-Uni] ; Désirée Van Der Heijde [Pays-Bas] ; Richard J. Wakefield [Royaume-Uni] ; Elizabeth M A. Hensor [Royaume-Uni] ; Maya H. Buch [Royaume-Uni]	Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial
000233 (2020)	Giulia Cassone [Italie] ; Marco Sebastiani [Italie] ; Caterina Vacchi [Italie] ; Stefania Cerri [Italie] ; Carlo Salvarani [Italie] ; Andreina Manfredi [Italie]	Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?
000244 (2020)	Przemysław Błyszczuk [Suisse, Pologne] ; Zoltan Szekanecz [Hongrie]	Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis
000257 (2020)	Stefanie Glaubitz ; Rachel Zeng ; Jens Schmidt	New insights into the treatment of myositis

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i -k "first" 

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i  \
                -Sk "first" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    first
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021